Chengdu Shilian Health Biotechnology Co., Ltd. was registered in August 2018, and was jointly established by the Chengdu Hi-tech Inustrial Development Zone, Chengdu West China Cell Therapy Research Institute Co., Ltd. (West China Hospital of Sichuan), Sichuan West China Maternal and Child Health Technology Co., Ltd. (West China Second University Hospital), Sichuan West China Oral Health Technology Co., Ltd. (West China Hospital of Stomatology Sichuan University), and the national "973" Professor Tian Weidong, the chief scientist of the key research and development plan project, jointly invested and initiated the establishment of an international first-class and high standard platform for cell technology and cell drug research and transformation application at the Chengdu Frontier Medical Center. Phase I has completed the construction of a 3500 square meter platform, including a national level cell information resource library (capable of storing cells for millions of people), regional cell preparation centers (adult stem cell, iPS cell, and immune cell preparation) in six independent cell production workshops that meet the highest international standards, and a cell quality testing and testing center that meets third-party services, forming a quality system that can be traced throughout the entire cycle of cell preparation, testing, and storage. Building on existing resources and platforms, we aim to create a high-tech biotechnology enterprise characterized by precision medicine and precision health, integrating cell technology research and development, achievement transformation, technical services, and talent cultivation.

        The established Sichuan Cell Bank Co., Ltd. under the platform company, relying on a century old West China research platform, including the State Key Laboratory, the National Local Joint Engineering Laboratory, several Ministry of Education and Sichuan Engineering Technology Research Center, has a multidisciplinary talent team and a perfect quality control system in the field of stem cells and regenerative medicine, and is committed to the construction of a high-quality human genetic cell information resource database Autologous cell storage services and stem cell product transformation will undertake the construction of the national adult stem cell resource bank and the national human genetic resource preservation center (Southwest Innovation Center), expand the platform's regional innovation and service capacity, research and production drive, and help clinical transformation of cell therapy and research and development of cell drugs.